Clinic for Zoo Animals, Exotic Pets and Wildlife, Vetsuisse Faculty, University of Zurich, 8057 Zurich, Switzerland.
School of Animal Sciences, Animal and Food Sciences Lab, Louisiana State University, Baton Rouge, LA 70803, USA.
J Avian Med Surg. 2022 May;36(1):39-52. doi: 10.1647/20-00075.
Egg binding and excessive laying frequently affect avian patients, and in many cases the treatment includes suppression of egg production. Currently, for the suppression of egg production in avian patients, a gonadotropin-releasing hormone agonist, in the form of a deslorelin implant, is often used. However, the commercially available deslorelin implants have an undesired delayed onset, as well as a potential brief increase in gonadotropin secretion after administration ("flare-up" effect) that can lead to oviposition before the actual suppression of gonadotropins. The objective of this study was to investigate whether the prolactin inhibitor cabergoline suppresses ovulation and whether it could be used to bridge the time until the onset of effect by the deslorelin implant. We measured the effect of cabergoline (30 µg/kg PO q24h × 14 days), deslorelin implants (4.7 mg SC), and a combination of both on egg laying and plasma prolactin concentrations in 37 quail () over 6 weeks. Quail were divided into 4 groups: group DesCab (deslorelin implant and cabergoline oral; n = 9); group DesPlac (deslorelin implant and placebo oral; n = 9); group PlacCab (placebo implant and cabergoline oral; n = 9); and group PlacPlac (placebo implant and placebo oral; n = 10). Regular egg laying stopped in 100% (9/9) of birds in group DesCab and 78% (7/ 9) of birds in group DesPlac within 5 days of placing the deslorelin implant. No bird ceased egg production in group PlacCab (0/9), and 10% of birds ceased egg production intermittently in group PlacPlac (1/10). Treatment with the deslorelin implant ( < .001) and with cabergoline ( = .04) had a significant (negative) influence on plasma prolactin concentrations compared with the baseline. The interaction of deslorelin and cabergoline treatment, as well as time after initiation of treatment, did not have a significant effect on plasma prolactin concentrations. These results show that daily oral cabergoline has no significant influence on egg laying and only a minor biologically nonsignificant effect on lowering the relative plasma prolactin concentrations in quail.
蛋滞产和过度产卵常影响禽类患者，在许多情况下，治疗包括抑制产卵。目前，在禽类患者中抑制产卵通常使用促性腺激素释放激素激动剂，即去势激素植入物的形式。然而，市售的去势激素植入物具有不理想的延迟起效，以及在给药后促性腺激素分泌短暂增加（“爆发”效应）的潜在风险，这可能导致排卵，而在促性腺激素实际被抑制之前。本研究旨在探讨催乳素抑制剂卡麦角林是否抑制排卵，以及它是否可用于通过去势激素植入物来弥合起效时间。我们测量了卡麦角林（30 µg/kg PO q24h × 14 天）、去势激素植入物（4.7 mg SC）和两者联合对 37 只鹌鹑（）在 6 周内产卵和血浆催乳素浓度的影响。鹌鹑被分为 4 组：组 DesCab（去势激素植入物和口服卡麦角林；n = 9）；组 DesPlac（去势激素植入物和口服安慰剂；n = 9）；组 PlacCab（安慰剂植入物和口服卡麦角林；n = 9）；和组 PlacPlac（安慰剂植入物和口服安慰剂；n = 10）。在放置去势激素植入物后 5 天内，组 DesCab 中 100%（9/9）的鸟类和组 DesPlac 中 78%（7/9）的鸟类停止产卵。组 PlacCab 中没有鸟类停止产卵（0/9），而组 PlacPlac 中有 10%的鸟类间歇性停止产卵（1/10）。与基线相比，去势激素植入物（<.001）和卡麦角林（=.04）的治疗对血浆催乳素浓度有显著（负）影响。去势激素和卡麦角林治疗的相互作用以及治疗开始后的时间对血浆催乳素浓度没有显著影响。这些结果表明，每日口服卡麦角林对产蛋没有显著影响，仅对降低鹌鹑的相对血浆催乳素浓度有轻微的生物学上无显著意义的影响。
